Anderson KE, Lobo R, Salazar D, Schloetter M, Spitzer G, White AL, et al. Biochemical diagnosis of acute hepatic porphyria: updated expert recommendations for primary care physicians. Am J Med Sci. 2021;362(2):113–21.

Article  PubMed  Google Scholar 

Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924–37.

Article  CAS  PubMed  Google Scholar 

Wang B, Rudnick S, Cengia B, Bonkovsky HL. Acute hepatic porphyrias: review and recent progress. Hepatol Commun. 2019;3(2):193–206.

Article  PubMed  Google Scholar 

Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439–50.

Article  PubMed  Google Scholar 

Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell DM, Bonkovsky HL, et al. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017;66:1314–22.

Article  PubMed  Google Scholar 

Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017;377(9):862–72.

Article  CAS  PubMed  Google Scholar 

Ramanujam VM, Anderson KE. Porphyria diagnostics-part 1: a brief overview of the porphyrias. Curr Protoc Hum Genet. 2015;86:17.20.1–17.20.6.

Wheeden K, Lyon Howe D, Burrell S, Gill L, Chamberlayne J, Williams ER, et al. Patient perspective on acute hepatic porphyria with sporadic attacks: a chronic disease with substantial health-related quality of life impacts. Adv Ther. 2022;39(9):4330–5.

Article  PubMed  PubMed Central  Google Scholar 

Stein PE, Edel Y, Mansour R, Mustafa RA, Sandberg S. Key terms and definitions in acute porphyrias: Results of an international Delphi consensus led by the European porphyria network. J Inherit Metab Dis. 2023;46(4):662–74.

Article  PubMed  Google Scholar 

Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014;127(12):1233–41.

Article  PubMed  PubMed Central  Google Scholar 

Buendía-Martínez J, Barreda-Sánchez M, Rodríguez-Peña L, Ballesta-Martínez MJ, López-González V, Sánchez-Soler MJ, et al. Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients. Orphanet J Rare Dis. 2021;16(1):106.

Article  PubMed  PubMed Central  Google Scholar 

Dickey A, Wheeden K, Burrell S, Falchetto R, Barman-Aksozen J, Bulkley A, et al. Impact of acute hepatic porphyria attack frequency on patient-reported outcomes: results from the Porphyria Worldwide Patient Experience Research (POWER) study [abstract FRI251]. J Hepatol. 2022;77(suppl 1):S516.

Article  Google Scholar 

Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, Stolzel U, et al. EXPLORE: a prospective, multinational, natural history study of patients with acute hepatic porphyria with recurrent attacks. Hepatology. 2020;71(5):1546–58.

Article  CAS  PubMed  Google Scholar 

Naik H, Stoecker M, Sanderson SC, Balwani M, Desnick RJ. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: a qualitative study. Mol Genet Metab. 2016;119(3):278–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stein PE, Badminton MN, Barth JH, Rees DC, Sarkany R, Stewart MF, et al. Acute intermittent porphyria: fatal complications of treatment. Clin Med (London). 2012;12(3):293–4.

Article  CAS  Google Scholar 

Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang B. The acute hepatic porphyrias. Transl Gastroenterol Hepatol. 2021;6:24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol. 2017;176(4):527–38.

Article  PubMed  Google Scholar 

Harper P, Sardh E. Management of acute intermittent porphyria. Expert Opin Orphan Drugs. 2014;2(4):349–68.

Article  CAS  Google Scholar 

Marsden JT, Guppy S, Stein P, Cox TM, Badminton M, Gardiner T, et al. Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. JIMD Rep. 2015;22:57–65.

Article  PubMed  PubMed Central  Google Scholar 

Bonkovsky HL, Dixon N, Rudnick S. Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs). Mol Genet Metab. 2019;128(3):213–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson KE. Acute hepatic porphyrias: current diagnosis & management. Mol Genet Metab. 2019;128(3):219–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Givlaari [package insert]. Cambridge, MA, USA: Alnylam Pharmaceuticals; 2023 February 2023.

Alnylam announces approval of GIVLAARI® (givosiran) in Brazil for the treatment of acute hepatic porphyria (AHP) in adults [press release] Sao Paulo, Brazil: Alnylam Pharmaceuticals; 2020 [July 20, 2020]. Available from: https://investors.alnylam.com/sites/default/files/GIVLAARI-Brazil-Approval-Press-Release.pdf.

Givlaari [summary of product characteristics] Amsterdam, The Netherlands: Alnylam Netherlands; 2021 [January 1, 2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/givlaari-epar-product-information_en.pdf.

Givlaari Canada [product monograph]. Amsterdam, Netherlands: Alnylam Netherlands; 2020 October 2020.

Givlaari, solution for injection (Givosiranum) Switzerland: swissmedic; 2021 [March 29, 2021]. Available from: https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/new-medicines/givlaari-injektionsloesung-givosiranum.html.

Obtained manufacturing and marketing approval for "Giblari" for the treatment of acute hepatic porphyria [press release] Tokyo, Japan: Alnylam Japan Co., Ltd.; 2021 [June 23, 2021]. Available from: https://www.alnylam.jp/sites/default/files/news-articles/Japan_Givo_Approval_Press_Release_0.pdf.

Balwani M, Sardh E, Ventura P, Peiró PA, Rees DC, Stölzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289–301.

Article  CAS  PubMed  Google Scholar 

Chan A, Liebow A, Yasuda M, Gan L, Racie T, Maier M, et al. Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol Ther Nucleic Acids. 2015;4: e263.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549–58.

Article  PubMed  Google Scholar 

Vassiliou D, Sardh E, Harper P, Najafian N, Simon A, Burke A, et al., editors. A drug-drug interaction study to investigate the effect of givosiran on the activity of 5 major drug metabolizing CYP450 enzymes in subjects with acute intermittent porphyria (AIP) who are chronic high excreters (CHE). International Congress on Porphyrins and Porphyrias; 2019 September 10, 2019; Milan, Italy.

Kuter DJ, Bonkovsky HL, Monroy S, Ross G, Guillén-Navarro E, Cappellini MD, et al. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial. J Hepatol. 2023;79(5):1150–8.

Article  CAS  PubMed  Google Scholar 

World Medical Association. WMA Declaration of Helsinki - ethical principles for medical research involving human subjects Ferney-Voltaire, France: World Medical Association; 2013 [Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/.

International Council for Harmonisation Working Group. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1): International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 1996 [June 10, 1996]. Available from: https://www.ich.org/page/efficacy-guidelines.

The Declaration of Istanbul on Organ Trafficking and Transplant Tourism: The Transplantation Society; 2018. Available from: https://www.declarationofistanbul.org/images/documents/doi_2018_English.pdf.

EuroQol Research Foundation. EQ-5D-5L User Guide. Rotterdam, Netherlands: EuroQol Research Foundation; 2019.

Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241–3.

Article  PubMed  Google Scholar 

Agarwal S, Habtemarium B, Xu Y, Simon AR, Kim JB, Robbie GJ. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels. JIMD Rep. 2021;57(1):85–93.

Article  PubMed  Google Scholar 

Simon A, Pompilus F, Querbes W, Wei A, Strzok S, Penz C, et al. Patient perspective on acute intermittent porphyria with frequent attacks: a disease with intermittent and chronic manifestations. Patient. 2018;11(5):527–37.

Article  PubMed  PubMed Central  Google Scholar 

Dickey A, Wheeden K, Lyon D, Burrell S, Hegarty S, Falchetto R, et al. Quantifying the impact of symptomatic acute hepatic porphyria on well-being via patient-reported outcomes: results from the Porphyria Worldwide Patient Experience Research (POWER) study. JIMD Rep. 2023;64(1):104–13.